New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 30, 2014
11:24 EDTNXST, APOL, ACHN, CBS, SBGI, VRTX, BBBY, FIO, MNKDOptions with decreasing implied volatility
Options with decreasing implied volatility: OHRP VRTX ACHN MNKD SBGI APOL FIO CBS NXST BBBY
News For VRTX;ACHN;MNKD;SBGI;APOL;FIO;CBS;NXST;BBBY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
March 23, 2015
09:38 EDTVRTXVertex shares defended at CRT Capital
Subscribe for More Information
09:37 EDTVRTXActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
09:28 EDTVRTXOn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTVRTXLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
07:47 EDTVRTXVertex says VX-661, ivacaftor generally well tolerated in 12-week Phase 2 study
Vertex Pharmaceuticals announced data from a 12-week Phase 2 study evaluating VX-661 in combination with ivacaftor in 39 people with CF ages 18 and older who have two copies of the F508del mutation. The study evaluated two doses of VX-661 in combination with ivacaftor. The primary endpoint of the study was safety. The study showed that the combination regimen was generally well tolerated, and all patients completed 12 weeks of treatment. The most common adverse events were pulmonary exacerbation, which occurred in 38% of all patients who received VX-661 and 44% of those who received placebo, and cough, which occurred in 33% of all patients who received VX-661 and 39% of those who received placebo. Secondary endpoints evaluated the effect of the combination on lung function, and the mean within-group absolute improvement from baseline in ppFEV1 for those who received 100 mg of VX-661 in combination with ivacafto was 4.4 and 3.0 percentage points at week 4 and through 12 weeks of treatment, respectively. Consistent with prior Phase 2 studies that evaluated 4 weeks of treatment with VX-661 in combination with ivacaftor, this study showed a rapid improvement in lung function within four weeks of treatment, and after patients completed treatment, lung function returned to baseline. These safety and efficacy data, together with other data from multiple previously completed Phase 2 studies of VX-661, support Vertex’s ongoing Phase 3 program of VX-661 in combination with ivacaftor. The Phase 3 program is evaluating VX-661 in combination with ivacaftor and consists of four Phase 3 studies, including a study in people with two copies of the F508del mutation that began enrollment in February. The other three studies will enroll people with CF who have one copy of the F508del mutation and a second mutation that is either a gating mutation, residual function mutation or a mutation that results in minimal CFTR function.
March 20, 2015
16:00 EDTMNKDOptions Update; March 20, 2015
Subscribe for More Information
08:13 EDTCBSCanada to 'unbundle' cable TV offerings by December 2016
Subscribe for More Information
06:36 EDTCBSWeb TV companies ask internet providers for special treatment, WSJ says
Subscribe for More Information
06:17 EDTCBSCBS price target raised to $72 from $60 at Citigroup
Citigroup raised its price target for CBS to $72 and calls the company the stock to own in the space amid changing industry dynamics. Citi sees upside to consensus estimates for 2016 and beyond from CBS's All Access subscriber expansion and Showtime over-the-top offering. It maintains a Buy rating on the name.
March 19, 2015
07:23 EDTCBSEvercore ISI to hold a tour
Subscribe for More Information
March 18, 2015
12:09 EDTCBSSony announces launch of PlayStation Vue in New York, Chicago, Philadelphia
Subscribe for More Information
09:32 EDTMNKDMannKind faces cash shortfall if $100M debt not settled, TheStreet says
Subscribe for More Information
09:23 EDTCBSVerizon may launch mobile TV service as soon as June, Bloomberg says
Verizon (VZ) has secured mobile television streaming rights with Viacom (VIA, VIAB) and DreamWorks Animation (DWA) and plans to start a mobile video streaming service as early as June, according to Bloomberg, citing a person familiar with the matter. Verizon plans to have programming from ABC (DIS), NBC (CMCSA), CBS (CBS) and Fox (FOXA) as part of the service, the report added. The Fly notes that Verizon has publicly confirmed previously that it plans to launch such a service, but has not provided many details to date.
March 17, 2015
17:19 EDTCBSTime Warner, CBS CEOs discussed possible merger last year, Bloomberg reports
CBS (CBS) CEO Les Moonves and Time Warner (TWX) CEO Jeff Bewkes had discussions about combining their companies in meetings last year, Bloomberg reports, citing three people with knowledge of the matter. Reference Link
15:56 EDTCBSTime Warner, CBS CEOs discussed possible merger last year, Bloomberg reports
Subscribe for More Information
13:06 EDTCBSBattleground: Analysts take opposite sides on Netflix
Subscribe for More Information
11:36 EDTCBSApple may launch standalone TV in 2016, says Piper Jaffray
Subscribe for More Information
March 16, 2015
11:20 EDTMNKDStocks with call strike movement; MNKD BBRY
Subscribe for More Information
07:39 EDTCBSViacom shareholder meeting may question Viacom, CBS control, NY Post says
Subscribe for More Information
March 15, 2015
18:14 EDTSBGISinclair Broadcast could return to around $37, Barron's says
Sinclair Broadcast is trading at around a 25% discount to peers and shares could return to a previous high of around $37.00, Barron's argues in its 'The Trader' column. Reference Link
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use